NCT06700083

A Safety, Tolerability, Pharmacokinetic Study of SHR-6934 Injection in Healthy Subjects

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Subcutaneous Injections of SHR-6934 in Healthy Subjects: a Randomized, Double-blind, Dose-escalation, Placebo-controlled Phase I Trial

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 88 (estimated)
• Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

This study was a randomized, double-blind, single-dose and multi-dose, placebo-controlled phase Ⅰ clinical trial. Six dose groups were planned for the SAD part of the study and four dose groups were planned for the MAD part. A total of 88 healthy subjects were included.

Conditions

• Heart Failure

Interventions

Type	Name	Description
DRUG	SHR-6934 injection	SHR-6934 injection
DRUG	SHR-6934 placebo	SHR-6934 placebo

Timeline

• Start date: 2024-11-01
• Primary completion: 2025-08-01
• Completion: 2025-08-01
• First posted: 2024-11-21
• Last updated: 2024-11-21

Locations

1 site across 1 country: China